Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-20122
- Development stage
- Phase 1
- Lead developer
- Hansoh BioMedical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HS-20122 is an **antibody-drug conjugate (ADC)** designed to target both the **Epidermal growth factor receptor (EGFR)** and **Hepatocyte growth factor receptor (c-Met)**. It is being developed for the treatment of advanced solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, and colorectal cancer. The drug was originated by Shanghai Hansoh Biomedical and is also associated with Changzhou Hansoh Pharmaceutical. As of 2025, it is in Phase 1 clinical trials evaluating its safety, tolerability, pharmacokinetics, and efficacy in advanced solid tumors. The specific payload of the ADC has not been publicly disclosed[2][4][6][10].
- Other names
- HS 20122HS20122HS-20122
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on HS-20122.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-20122.